文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

欧洲多重耐药淋病奈瑟菌克隆的公共卫生监测:一项基因组学调查

Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey.
PubMed 文献 · Lancet Infect Dis · 2018-05-15

该研究对2013年9月至11月20个欧洲国家淋病患者的1054株分离株进行全基因组测序,并结合流行病学与表型数据分析淋球菌种群。研究发现多重耐药NG-MAST基因群G1407仍是主要克隆,但其占比由2009-10年的248/1066株(23%)降至174/1054株(17%),且其关联人群由男男性行为者转为异性恋人群(OR=4.29);全基因组测序的分辨率和耐药预测优于NG-MAST与多位点序列分型。

要点

  • 多重耐药NG-MAST基因群G1407占比由23%(248/1066)降至17%(174/1054)。
  • G1407的关联人群由男男性行为者转为异性恋人群,OR=4.29。
  • 全基因组测序的分辨率与耐药预测优于NG-MAST和多位点序列分型。

核心结论

  • 研究提供了全基因组测序与流行病学数据联合用于性传播感染区域监测的首次应用,增进了对耐药克隆分布(包括被更敏感克隆替代)的理解。
  • 研究提出通过标准化采样、全基因组测序和开放获取软件共享信息架构开展淋球菌基因组监测的框架。

研究设计与样本

  • 观察性研究,对2013年9月至11月欧洲淋球菌抗菌药物监测规划中20个国家淋病患者分离株进行测序,共分析1054株分离株。
  • 建立网络平台用于自动化耐药预测、分子分型(NG-MAST和多位点序列分型)及结合流行病学与表型数据的系统发育聚类。

主要发现

  • 多重耐药NG-MAST基因群G1407占主导并贡献最多头孢菌素耐药,其占比由2009-10年研究的248/1066株(23%)降至2013年本调查的174/1054株(17%)。
  • G1407此前与男男性行为者相关,本次转为与异性恋人群相关(OR=4.29)。
  • 全基因组测序较NG-MAST和多位点序列分型分辨率和准确性显著提高,耐药预测相对良好,并识别出差异分离株、混合感染或污染以及关联风险组的多重耐药分支。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditional methods for molecular epidemiology of Neisseria gonorrhoeae are suboptimal. Whole-genome sequencing (WGS) offers ideal resolution to describe population dynamics and to predict and infer transmission of antimicrobial resistance, and can enhance infection control through linkage with epidemiological data. We used WGS, in conjunction with linked epidemiological and phenotypic data, to describe the gonococcal population in 20 European countries. We aimed to detail changes in phenotypic antimicrobial resistance levels (and the reasons for these changes) and strain distribution (with a focus on antimicrobial resistance strains in risk groups), and to predict antimicrobial resistance from WGS data. METHODS: We carried out an observational study, in which we sequenced isolates taken from patients with gonorrhoea from the European Gonococcal Antimicrobial Surveillance Programme in 20 countries from September to November, 2013. We also developed a web platform that we used for automated antimicrobial resistance prediction, molecular typing (N gonorrhoeae multi-antigen sequence typing [NG-MAST] and multilocus sequence typing), and phylogenetic clustering in conjunction with epidemiological and phenotypic data. FINDINGS: The multidrug-resistant NG-MAST genogroup G1407 was predominant and accounted for the most cephalosporin resistance, but the prevalence of this genogroup decreased from 248 (23%) of 1066 isolates in a previous study from 2009-10 to 174 (17%) of 1054 isolates in this survey in 2013. This genogroup previously showed an association with men who have sex with men, but changed to an association with heterosexual people (odds ratio=4·29). WGS provided substantially improved resolution and accuracy over NG-MAST and multilocus sequence typing, predicted antimicrobial resistance relatively well, and identified discrepant isolates, mixed infections or contaminants, and multidrug-resistant clades linked to risk groups. INTERPRETATION: To our knowledge, we provide the first use of joint analysis of WGS and epidemiological data in an international programme for regional surveillance of sexually transmitted infections. WGS provided enhanced understanding of the distribution of antimicrobial resistance clones, including replacement with clones that were more susceptible to antimicrobials, in several risk groups nationally and regionally. We provide a framework for genomic surveillance of gonococci through standardised sampling, use of WGS, and a shared information architecture for interpretation and dissemination by use of open access software. FUNDING: The European Centre for Disease Prevention and Control, The Centre for Genomic Pathogen Surveillance, Örebro University Hospital, and Wellcome.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Harris SR, Cole MJ, Spiteri G, et al. Public health surveillance of multidrug-resistant clones of Neisseria gonorrhoeae in Europe: a genomic survey. Lancet Infect Dis. 2018. PMID: 29776807. doi:10.1016/S1473-3099(18)30225-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。